Cardiovascular disease is the number-one health problem worldwide.
Development of therapeutic approaches depends on suitable small and large animal models that replicate pathogenesis in humans.
Non-coding RNAs are novel therapeutic targets as master regulators of gene expression by controlling many physiologic and pathologic processes.
Our primary focus is to develop synthetic antisense oligonucleotide based therapeutics targeting specific non-coding RNAs as a revolutionary pharmacological tool fighting cardiovascular diseases.
1. Non-coding RNA based therapy of heart failure
We aim to develop and test noncoding RNA-based therapies in small and large animal models of myocardial infarction and heart failure.
2. Antisense oligo pharmacology
Pharmacological characterization of synthetic non-coding RNA inhibitors
Dr. Ariana Foinquinos, Group Leader
Dr. med. vet. Heike Janssen
Markus Herkt, PhD-student
Karina Zimmer, Technician
Janet Remke, Technician
Nicole Ernst, Technician